Repligen Corporation $RGEN Shares Purchased by Avidity Partners Management LP

Avidity Partners Management LP lifted its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 115.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,300 shares of the biotechnology company’s stock after buying an additional 27,000 shares during the quarter. Repligen comprises approximately 2.4% of Avidity Partners Management LP’s investment portfolio, making the stock its 10th biggest holding. Avidity Partners Management LP’s holdings in Repligen were worth $8,242,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the 3rd quarter worth approximately $29,000. Bayforest Capital Ltd acquired a new stake in shares of Repligen during the 4th quarter worth approximately $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC grew its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after buying an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of several analyst reports. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. HSBC lowered their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company lowered their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Down 2.1%

Shares of NASDAQ RGEN opened at $130.59 on Friday. The stock has a market cap of $7.37 billion, a P/E ratio of 145.10, a P/E/G ratio of 2.51 and a beta of 1.09. The firm has a 50 day moving average price of $120.23 and a 200 day moving average price of $137.90. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.